Ligand Pharmaceuticals Incorporated LGND announced the sale of all rights to Novartis’ NVS blockbuster drug, Promacta (eltrombopag), to privately-held Royalty Phamra for $827 million. The sale also ...
GlaxoSmithKline and the FDA notified healthcare professionals of a new safety finding in patients with thrombocytopenia due to chronic liver disease treated with Promacta (eltrombopag tablets). The ...
First supportive care treatment approved for patients with thrombocytopenia with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy LONDON, Nov. 19, 2012 ...
PHILADELPHIA, Dec. 6 GlaxoSmithKline (NYSE: GSK)announced positive safety and efficacy results from RAISE (RAndomized placebo-controlled ITP Study with Eltrombopag), a Phase III study of ...
(HealthDay)—U.S. Food and Drug Administration approval of the drug Promacta (eltrombopag) has been expanded to include children one year and older with a rare blood disorder called chronic immune ...
Recently, the FDA granted a breakthrough therapy designation to eltrombopag (Promacta, Novartis) for combination use with standard immunosuppressive therapy as a first-line treatment for patients with ...
The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called ...
PHILADELPHIA, Feb. 25, 2011 /PRNewswire/ -- GlaxoSmithKline (NYSE: GSK) today announced that the United States Food and Drug Administration (FDA) granted full approval for PROMACTA® (eltrombopag), an ...
The company is recalling the lots because of possible peanut flour contamination. Novartis announced on May 11, 2019 that it was recalling three lots of Promacta (eltrombopag) 12.5 mg for oral ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio The FDA granted priority review ...
Patients began once daily treatment with PROMACTA at 50 mg (or matching placebo) with doses individualized based upon each patient's platelet response, ranging from once-daily doses of 25 mg to 75 mg, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results